Interestingly, clinical trials assessing the role of curcumin in AD treatment have focused more on its anti‐Aβ and neuroprotective properties rather than direct tau inhibition.[310] However, ongoing research is addressing formulation challenges to enhance its efficacy. Here, MAPT is linked to Alzheimer disease.